Mr. Toshiyuki Ishii, a member of the Board of Directors and the current CEO and Legal Representative of Hau Giang Pharmaceutical, will step down from his roles as CEO and Legal Representative effective January 1, 2026.
Hau Giang Pharmaceutical Joint Stock Company (HoSE: DHG) has announced significant leadership changes. Mr. Toshiyuki Ishii, who serves as a Board Member, CEO, and Legal Representative, will relinquish his positions as CEO and Legal Representative starting January 1, 2026, marking the end of his three-year term (2023–2025).
Born in 1966, Mr. Toshiyuki Ishii is a Japanese national. Prior to his tenure at Hau Giang Pharmaceutical, he held the position of Chairman and Director at Taisho Indonesia.
The Board of Directors has appointed Mr. Toshifumi Kojima as the Acting CEO and Legal Representative for a six-month period beginning January 1, 2026. Following this interim period, the Board and Human Resources Committee will evaluate Mr. Kojima’s performance and consider his formal appointment as CEO for a three-year term until December 31, 2028.
Additionally, the company has reappointed Mr. Osamu Fujimori as Chief Operating Officer (COO) from January 1, 2026, to December 31, 2026. Mr. Tomoyuki Kawata will continue as Deputy CEO in charge of production and technology transfer, and Ms. Nguyen Ngoc Diep will remain Deputy CEO overseeing production, both serving until December 31, 2028.
Hau Giang Pharmaceutical is Vietnam’s largest pharmaceutical manufacturer, maintaining its industry-leading position for nearly 30 years. According to IMS Q4/2024, the company ranks among the top three pharmaceutical firms with the largest market share in Vietnam.
In Q3/2025, Hau Giang Pharmaceutical reported net revenue of VND 1,145.7 billion, an 8% increase year-over-year, with post-tax profit reaching VND 210 billion, up 34.3%. The company attributed this growth to a robust recovery in the Pharmacy channel, cost optimization, and improved operational efficiency.
For the first nine months of 2025, the company generated over VND 5,524 billion in revenue, a slight increase, with pre-tax profit at VND 800 billion and post-tax profit nearing VND 713 billion, a 25% rise compared to the same period in 2024. These results represent 106% of the revenue target and 85% of the pre-tax profit target for the year.
Vietnam’s Most Populous City to Construct 4-Level Interchange and 12,000 Billion VND Road Network, Aiming to Alleviate Eastern Gateway Congestion
The Go Cong Interchange, seamlessly connecting to Ring Road 3, boasts a sophisticated 4-tier design featuring multiple overpasses and underpasses. This innovative structure significantly enhances traffic connectivity in the eastern region of Ho Chi Minh City.
Three Architectural Giants Compete for Gia Binh Airport Passenger Terminal Design: Masterminds Behind the World’s Tallest Buildings and Iconic Vietnamese Projects
Gia Bình International Airport is poised to become a major aviation hub, with projected capacity to handle 30 million passengers and 1.6 million tons of cargo annually by 2030. This ambitious plan further expands to accommodate 50 million passengers and 2.5 million tons of cargo per year by 2050.
The $9 Billion Paradox of Vietnam’s Pharmaceutical Industry: The Combined Market Value of the Top 10 Local Companies Still Trails Behind a Single Indonesian Giant
The pharmaceutical industry in Vietnam is dominated by DHG, a company with a market capitalization of approximately 511 million USD. In contrast, Indonesia’s leading pharmaceutical company, PT Kalbe Farma Tbk (KLBF), boasts a significantly higher market cap of nearly 3.9 billion USD.
